Clinical Trials Browser

Leukemia, Myelogenous, Chronic, BCR-ABL Positive × olverembatinib × 90 days × Clear all

NCT06817720 2026-05-20

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive